stockportfolio.pro
Guardant Health, Inc. (GH)
Healthcare · Diagnostics & Research · NasdaqGS
Guardant Health, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.25M | $49.84M | $90.64M | $214.38M | $286.73M | $373.65M | $449.54M | $563.95M | $739.02M | $982.02M |
| Gross profit | — | — | — | — | — | — | $293.21M | $336.90M | $449.22M | $633.01M |
| Net income | $-46.14M | $-83.22M | $-85.06M | $-75.65M | $-246.28M | $-384.77M | $-654.59M | $-479.45M | $-436.37M | $-416.28M |
| Net margin | -182.7% | -167.0% | -93.8% | -35.3% | -85.9% | -103.0% | -145.6% | -85.0% | -59.0% | -42.4% |
Source: Guardant Health, Inc. SEC filings (10-K).
Explore 10 years of Guardant Health, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeGuardant Health, Inc. financial history by metric
About Guardant Health, Inc.
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liquid test, which measures 740+ genes and supports all guideline-recommended biomarkers; Guardant Reveal test, a blood test that utilizes circulating tumor DNA to detect cancer at the molecular level; and Guardant360 Tissue test, a molecular profiling test for tumor tissue that provides genomic, transcriptomic, and epigenomic insights. It also provides Shield blood test for colorectal cancer screening in adults. In addition, the company offers GuardantINFINITY test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantOMNI test covers 500 genes, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications; GuardantINFORM, which provides longitudinal biological insight into tumor evolution alongside longitudinal clinical outcomes; and GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies. Further, it provides Smart Platform, which delivers multiomic insights leveraging genomic, epigenomic, and RNA-based data that are scalable from research to the clinic. Additionally, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. It has a strategic collaboration with Nuvalent, Inc. for oncology drug development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Guardant Health, Inc. — frequently asked questions
What is Guardant Health, Inc.'s revenue?
Guardant Health, Inc. (GH) reported revenue of $982.02M for fiscal year 2025, up 32.9% from the prior year, according to its SEC filings.
Is Guardant Health, Inc. profitable?
No — GH reported a net loss of $-416.28M in fiscal 2025.
What is GH's P/E ratio?
Guardant Health, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Guardant Health, Inc. growing?
GH's revenue grew at roughly 27.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Guardant Health, Inc. have?
As of fiscal year 2025, GH carried roughly $1.50B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Guardant Health, Inc.'s gross margin?
GH's gross margin was 64.5% in fiscal 2025 — gross profit of $633.01M on revenue of $982.02M.
What is Guardant Health, Inc.'s market cap?
Guardant Health, Inc. (GH) has a market capitalization of about $17.41B, based on the latest data in our nightly-refreshed cache.
When does Guardant Health, Inc.'s fiscal year end?
GH's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Guardant Health, Inc.'s official SEC filings (10-K and 10-Q), covering 10 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.